Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

272 results about "Polypeptide chain" patented technology

Each polypeptide chain consists of smaller sub-units or amino acids that are linked together. Amino acids serve as the building blocks of polypeptides, and polypeptides serve as the building blocks of proteins.

Tetrahedral antibodies

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.
Owner:BIOMOLECULAR HOLDINGS LLC

Tetrahedral antibodies

The present invention provides a tetrahedral antibody comprising a first domain, a second domain, a third domain, and a fourth domain wherein each of the first domain and the second domain is selected from the group consisting of a Fab domain and an Fc domain, wherein each of the first domain and the second domain comprises a first polypeptide chain comprising a first N-terminus and a first C-terminus of the domain, and a second polypeptide chain comprising a second N-terminus and a second C-terminus of the domain, wherein the first structural domain and the second structural domain are connected between a first N end of the first structural domain and a first N end of the second structural domain and between a first C end of the first structural domain and a first C end of the second structural domain; non-peptidyl linkages between the first N-terminus of the first domain and the first C-terminus of the second domain or between the first C-terminus of the first domain and the first N-terminus of the second domain are joined to each other.
Owner:BIOMOLECULAR HOLDINGS LLC

Resin composition, medical material, and method for producing resin composition

Provided is a resin composition that contains a first polymer compound and a second polymer compound. The first polymer compound has, in the main chain, a first repeat unit in which a plurality of amino acid residues are bonded by peptide bonds. The second polymer compound has, at a terminal of a side chain, a peptide chain or polypeptide chain in which a plurality of amino acid residues are bonded by peptide bonds. The plurality of amino acid residues constituting the first repeat unit of the first polymer compound contains amino acid residues deriving from at least two amino acids selected from the group consisting of glycine, alanine, serine, tyrosine, and valine. The plurality of amino acid residues constituting the peptide chain or polypeptide chain of the second polymer compound contains amino acid residues deriving from at least two of the amino acids that constitute the first repeat unit.
Owner:NAT UNIV CORP TOKYO UNIV OF AGRI & TECH

Preparation method of polymer vesicle capable of crossing blood brain barrier

The invention discloses a preparation method of a polymer vesicle capable of crossing a blood brain barrier, and belongs to the field of high polymer materials and medical engineering. The preparation method of the polymer vesicle capable of crossing the blood brain barrier comprises the following steps: synthesizing an amphiphilic block copolymer by utilizing ring-opening polymerization reaction of polycaprolactone and anhydride in an amino acid ring, then assembling the polymer into the polymer vesicle, and modifying a monoclonal antibody of a transferrin receptor on a polypeptide chain. The polymer vesicle prepared by the invention is simple and convenient in preparation process, short in period, good in stability, good in biocompatibility and good in biodegradability, can be used as an excellent carrier of chemotherapeutic drugs, and can effectively realize drug delivery of targeting brain tumor cells across a blood brain barrier. Compared with a commercial drug delivery carrier, the polymer vesicle has the advantage that the permeability of the drug in a bionic blood brain barrier and the targeted uptake rate of brain tumor cells are remarkably improved.
Owner:JIANGNAN UNIV

Heterodimer molecule based on CH3 domain, and preparation method and use thereof

The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise specific substitution mutations combination, for example, for the first CH3 domain: T366W+F405K, and for the second CH3 domain: T366S+L368A+Y407V+K409A.
Owner:JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD +1

Dimeric antigen receptors

The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.
Owner:OQORY INC

Artificial sensor element combination, nucleic acid encoding same, recombinant expression vector containing nucleic acid, host cell and application thereof

The invention discloses an artificial sensor element combination, nucleic acid for coding the artificial sensor element combination, a recombinant expression vector containing the nucleic acid, a host cell and application of the artificial sensor element combination. The artificial sensor element combination comprises a polypeptide chain 1, a polypeptide chain 2 and a specific substrate, and the method is used for high-throughput detection of protein solubility, stability and enzyme activity. When the artificial sensor element combination is used for detecting protein properties, the problems of inaccuracy, false positive and the like of soluble detection of a conventional protein soluble sensor caused by dynamic characteristics of protein expression, folding and aggregation processes can be at least solved.
Owner:TSINGHUA UNIVERSITY +1

Method for separating egg white polypeptide chain by adopting coupling membrane

The invention discloses a method for separating an egg white polypeptide chain by adopting a coupling membrane, and particularly relates to the field of egg white polypeptide chains, the method comprises the following steps: S1, mixing fresh egg white with a buffer solution, adjusting the initial acid-base environment and initial temperature of a system, and measuring key basic parameters after dispersion treatment; s3, introducing the pretreated egg white liquid into a first-stage membrane assembly, monitoring separation process parameters, obtaining interception efficiency, dynamically adjusting operation parameters, and enabling permeate liquid to enter a second-stage membrane assembly; s7, monitoring system environment parameters and polypeptide activity, obtaining an activity retention rate, dynamically adjusting supply parameters, and maintaining the polypeptide activity; s8, classifying and collecting products according to molecular weight intervals, evaluating comprehensive separation efficiency, completing separation and verifying product indexes; by constructing an ultrafiltration membrane-nanofiltration membrane-reverse osmosis membrane three-stage coupling separation system and combining a dynamic parameter adjustment mechanism based on interception efficiency, separation selectivity and refined purity, the purity and separation efficiency of a polypeptide product are remarkably improved.
Owner:WUXI YIZHU BIOTECHNOLOGY CO LTD

Smeglutide

The invention provides semeglutide, which is synthesized by adopting the following method, and the specific steps are as follows: 1) segmenting the main chain of semeglutide into three polypeptide fragments: 7-14 sites, 15-22 sites and 23-37 sites; (2) respectively preparing the 7-14-site fragments, the 15-22-site fragments and the 23-37-site fragments through solid-phase synthesis; 3) connecting the 7-14-site fragment with the 15-22-site fragment to form a 7-22-site fragment, and activating the C end of the fragment into active ester; (4) selectively removing an Alloc protecting group of Lys26 in the 23-37-site fragment, and then carrying out fatty acid modification to obtain a modified 23-37-site fragment; 5) in a liquid phase system, coupling the activated 7-22-site fragment and the modified 23-37-site fragment according to a molar ratio of 1: (0.6-1.4) to form a complete polypeptide chain; and 6) removing the protecting group and purifying to obtain a semaglutide finished product. The method provided by the invention can effectively realize high-purity, high-yield and low-cost synthesis of the semeglutide bulk drug.
Owner:SICHUAN OPEN MEDICINE CO LTD

Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity

A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
Owner:GENZYME CORP

Trispecific binding proteins, methods, and uses thereof

Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.
Owner:SANOFI SA(FR)

In-situ cross-linked polypeptide gel as well as preparation method and application thereof

The invention relates to in-situ cross-linked polypeptide gel and a preparation method and application thereof, and the preparation method comprises the following steps: dissolving modified polypeptide in a first solvent to obtain a component A; dissolving an amino high-molecular polymer in a second solvent to obtain a component B; mixing the component A and the component B to obtain in-situ cross-linked polypeptide gel; the modified polypeptide is mainly obtained by reacting a compound containing an NHS group with polypeptide under the action of a catalyst. The preparation method of the in-situ cross-linked polypeptide gel is simple in condition, easy to operate, mild in reaction condition, simple and easily available in raw materials, safe and good in biocompatibility, and has a wide application prospect. The prepared hydrogel containing the polypeptide chain is good in toughness, good in viscosity, good in biocompatibility, high in biological safety, biodegradable, good in plasticity, non-toxic and harmless.
Owner:JIANGSU DEVICELAND MEDICAL INSTR CORP LTD +2

Trispecific binding proteins, methods, and uses thereof

ActiveUS12227573B2Tumor targetProtein target
Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.
Owner:SANOFI SA(FR)

Bivalent, bispecific binding proteins for prevention or treatment of HIV infection

Provided herein are compositions comprising trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins for the treatment and / or prevention of HIV / AIDS.
Owner:SANOFI SA(FR)

Trispecific binding proteins, methods and uses thereof

To provide trispecific and / or trivalent binding proteins.SOLUTION: Disclosed herein is a trispecific and / or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, where a first pair of the polypeptides that form the binding protein possesses double binding domains having crossover tropism, and a second pair of the polypeptides has a single variable domain that forms a single antigen binding site. In some embodiments, the binding protein comprises a binding site that binds to CD28 polypeptide, a binding site that binds to CD3 polypeptide, and a binding site that binds to a third polypeptide that binds to, for example, a tumor targeting protein.SELECTED DRAWING: Figure 1A
Owner:SANOFI SA(FR)

Trispecific binding proteins, methods, and uses thereof

Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.
Owner:SANOFI SA(FR)

Preparation method of recombinant cell, recombinant cell and application of recombinant cell

The invention provides a preparation method of a recombinant cell, the recombinant cell and application of the recombinant cell, and relates to the technical field of biology. A target protein expressed by the recombinant cell contains one, two, three or four polypeptide chains; the preparation method comprises the following steps: integrating exogenous polynucleotides for coding a target protein into a genetic material of a starting cell in a site-specific manner, wherein each exogenous polynucleotide for site-specific integration contains coding genes of all polypeptide chains of the target protein; each exogenous polynucleotide contains at least four expression cassettes, and each polypeptide chain is encoded by at least one expression cassette. The preparation method is simple to operate, coding genes of all polypeptide chains can be integrated into genetic materials of starting cells at a time, and the expression quantity of foreign proteins of the recombinant cells obtained through the preparation method is high.
Owner:SHENZHEN TAILI BIOTECHNOLOGY CO LTD

Rapid-acting insulin analogues of enhanced stability

A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at position A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
Owner:CASE WESTERN RESERVE UNIV

Reduced fragmentation of anti-alpha-beta TCR binding polypeptides

This invention provides an antibody composition with improved stability, exhibiting reduced fragmentation of the antibody polypeptide chain during manufacturing and subsequent storage. [Solution] This disclosure relates to improved compositions and methods for treating T cell-mediated diseases and disorders (e.g., autoimmune disorders, graft-versus-host diseases, and graft rejection). Provided are antibody-containing anti-αβTCR binding polypeptides comprising at least one amino acid substitution or modification that enhances the stability of the binding polypeptide by reducing fragmentation of the light chain variable region. Methods provided herein generally involve administering an effective amount of a stabilized, humanized binding polypeptide specific to the alpha-beta T cell receptor (αβTCR) to a subject in need thereof.
Owner:GENZYME CORP

Three-specificity immune cell adapter-cytokine fusion protein, and preparation method and application thereof

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.
Owner:NANJING DRUM TOWER HOSPITAL

Thrombin cleavable linker with xten and its uses thereof

To provide a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker.SOLUTION: The present invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, and a chain comprising a VWF protein and a chain comprising a FVIII protein are associated with each other. The method also comprises a method for using a nucleotide, a vector, a host cell, and a chimeric protein.SELECTED DRAWING: None
Owner:BIOVERATIV THERAPEUTICS INC

Immunoglobulin-binding protein, and affinity carrier using same

An affinity carrier may have improved alkali resistance. An immunoglobulin-binding protein containing a mutant polypeptide chain, as well as an affinity carrier containing a solid-phase carrier to which the immunoglobulin-binding protein is bound, may be a mutant polypeptide chain having an amino acid sequence having at least 85% identity to an amino acid sequence indicated by any of SEQ ID NO: 1-6 and 57-62, having a predetermined mutation, and having immunoglobulin-binding activity.
Owner:MERCK PATENT GMBH

Protein-based adhesive and its modification

ActiveUS12331230B2Connective tissue peptidesSurgical adhesivesSurgical operationElastin like polypeptides
This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP) that contain tyrosine, lysine, cysteine, dihydroxyphenylalanine (DOPA) or trihydroxyphenylalanine (TOPA) amino acid residue, or a combination thereof, on the polypeptide chain of said ELP. Among others, the adhesives disclosed herein may find broad applications in medical treatments and surgical operations. Compositions and methods of use are within the scope of this application.
Owner:PURDUE RES FOUND

Recombinant hemoglobin, nucleic acid encoding same, and preparation method therefor

A recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, and a preparation method therefor are provided to address the current problems of complex processes, high production costs, and low yields that exist for improving a hemoglobin having a stable tetrameric structure. The recombinant hemoglobin comprises: two or more units of recombinant hemoglobins, the units of recombinant hemoglobins each comprise four polypeptide chains, and the polypeptide chains are two α chains and two β chains. The amino acid sequences of the four polypeptide chains of each unit of recombinant hemoglobin are linked by means of intra-unit linker peptides to form the unit of recombinant hemoglobin, and two or more of the units are linked by means of inter-unit linker peptides.
Owner:KANGMA (SHANGHAI) BIOTECH LTD

Targeted T cell and Her2 positive cell bispecific antibody fusion protein connected in series with 4-1BBL and application thereof

The invention discloses a bispecific antibody targeting T cells and Her2 positive cells and a fusion protein connected in series with 4-1BBL. Belongs to the technical field of biology. The fusion protein is of a heterotetramer structure formed by connecting two similar heavy polypeptide chains and two similar light polypeptide chains through disulfide bonds, wherein the similar heavy polypeptide chains comprise a heavy chain variable region of a Her2 targeting antibody, a human IgG1 Fc region and a human 4-1BBL extracellular region; the light polypeptide-like chain comprises a light chain variable region of a Her2 targeting antibody, a human antibody light chain constant region and a single chain variable region fragment of a CD3 targeting antibody. The fusion protein can specifically bind to Her2 positive tumor cells and CD3 molecules on the surfaces of T cells at the same time, and provides a key co-stimulation signal by using 4-1BBL connected in series, so that the killing function of the T cells is efficiently activated and enhanced in the local part of the tumor. The fusion protein provides a novel candidate strategy with stronger curative effect, more lasting effect and better safety for immunotherapy of Her2 positive tumors.
Owner:BEIJING ZAIQING BIOTECHNOLOGY CO LTD

Protein sequence phosphorylation site prediction method and system, computer equipment and storage medium

The invention discloses a protein sequence phosphorylation site prediction method and system, computer equipment and a storage medium, and relates to the technical field of protein sequence phosphorylation site prediction.The protein sequence phosphorylation site prediction method includes the steps that data collection is conducted on an amino acid sequence of a protein and a corresponding phosphorylation site, preprocessing is conducted in an automatic labeling mode, and a prediction result is obtained; dividing the protein sequence into a plurality of polypeptide chains through sliding window calculation; the method comprises the following steps: coding an amino acid sequence based on a BERT protein language model, extracting protein information features, calculating an emission score and a transfer score by taking a conditional random field (CRF) as a decoder, capturing regional distribution and a tandem effect of phosphorylation sites, and carrying out loss calculation by taking a negative likelihood logarithm (NNL) as a loss function, protBERT is adopted as a main framework for extracting protein sequence information to carry out establishment and training of a phosphorylation prediction model; and carrying out phosphorylation prediction through the phosphorylation prediction model. According to the method, the labor cost and the time cost are greatly reduced.
Owner:NANJING AGRICULTURAL UNIVERSITY +1

Protein molecule of interleukins 12a and b combined with additional factors

A protein molecule that includes interleukin 12a (IL12a), interleukin 12b (IL12b), a first factor and a second factor located in the same polypeptide chain that can be used for treating tumors.
Owner:NINGBO INNOVATIVE MECHANISM BIOSCIENCE LLC

Method for modifying polypeptide with decarboxylated boric acid and trifluoroboric acid

PendingCN120607579APeptide preparation methodsAspartic acid residueFluoroboric acid
The invention discloses a method for modifying polypeptide with decarboxylated boric acid and trifluoroboric acid, which comprises the following steps: under a solid phase condition, carrying out active esterification reaction on polypeptide I under a condition (i) to prepare active esterified polypeptide II; then reacting the active esterified polypeptide II with a boric acid source under the action of a condition (ii) to form a borated polypeptide III; finally, under the condition (iii), the boric acid polypeptide III is subjected to fluorination treatment, and the trifluoroborate polypeptide IV is obtained. According to the method disclosed by the invention, decarboxylation and boric acid acidification of glutamic acid or aspartic acid residues in a polypeptide chain can be specifically realized, and controllable introduction of a trifluoroboric acid group is further completed.
Owner:SHENZHEN TECH UNIV

Aminoacyl-tRNA synthetases and uses hereof

ActiveUS12509675B2LigasesFermentationOrganic chemistryAminoacylation
The invention relates to aminoacyl-tRNA synthetases that aminoacylate tRNA with 2-Aminoisobutyric acid (Aib), thus enabling the incorporation of the Aib into a growing polypeptide chain during translation, e.g. in eubacterial host cells such as E. coli. For example, but not limited to, the invention relates to new aminoacyl-tRNA synthetases and the uses hereof, as well as a method for producing polypeptides that contain one or more Aib.
Owner:NOVO NORDISK AS